Business
Apellis is a commercial-stage biopharma company focused on complement inhibition, with marketed drugs SYFOVRE and EMPAVELI.
Apellis revenue rose 28.5% to $1.0B, turning net income and free cash flow positive.
The read at a glance✓ Audited against SEC data
- Business mix — Complement therapeuticsNote
- Revenue — Revenue rose 28.5% to $1.0BOK
- Profitability — Net income turned positiveOK
- Cash — FCF turned positive at $45.0MOK
- Balance sheet — Equity rose 62.0%OK
- Insiders — 0 buys / 43 sellsWatch
- Accounting — Altman-Z distress; EQ safeWatch
Where the revenue comes from
Fiscal 2025, as Apellis Pharmaceuticals, Inc. reports it. History and quarterly detail are in the app.
- Product$689.4M
- Syfovre$586.9M
- Licensing And Other Revenue$314.4M
- Empaveli Pegcetacoplan$102.4M
Leadership changes
From Apellis Pharmaceuticals, Inc.'s own filings, the day they're filed.
- Adam Townsend · Chief Operating Officer · appointmenteff. 2024-01-16
- Wharton School · director · appointment
- Craig A. Wheeler · director · departure
Latest filings
- 8-K · Company announcement2026-05-14
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-04
- 8-K · Company announcement2026-03-31
- 8-K · Company announcement2026-03-02
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Apellis Pharmaceuticals, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.